Re: Don't get greedy with Nvax...Motley Fool
Novavax asked the DMSB if the vaccine was showing efficacy against the primary endpoint of at least 40%. The DMSB simply answered YES. End of story. Novavax then calculated the 45%-100% efficacy based on some undisclosed assumptions. Others here went through the math I believe, but I don’t remember anyone from Novavax stating exactly how they came up with the number. Erck tried to explain it to somebody on this board in an email response, but nothing publicly that I am aware of.